General Toxicity Notes
Dosage guided by blood glucose levels.
Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
2-4/Increased
Plasma Protein Binding %
5
Volume Of Distribution L/Kg
0.15
Dose For Normal Renal Function
Variable
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [A]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate
References
Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs. 1987; 34: 350-71. [PMID: 3315622] / Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352: 174-83. [PMID: 15647580] / Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med. 1970; 282: 182-7. [PMID: 5409813]
Toxicity Notes
Renal metabolism of insulin decreases with azotemia.